CONTACT US

Circa Group Pty Ltd
Bio21 Molecular Science
& Biotechnology Institute
30 Flemington Road, Parkville
VIC 3010 Australia
Twitter @circagroup

Tony Duncan
Chief Executive Officer
Tony.Duncan@circagroup.com.au

Warwick Raverty
Chief Scientist
Warwick.Raverty@circagroup.com.au

c/o Bio 21, Flemington Road
Melbourne
Australia

+61 419 303 117

Circa Group is converting waste biomass into advanced biochemical materials.

News

Circa and Norske Skog on cusp of delivering a new bio-chemicals industry for Tasmania

Nigel Rowe

Mr Eric Hutchinson, Federal MP for Lyons, Mr John Laugher, Vice President Strategy and Business Development at Norske Skog, Mr Tony Duncan, CEO of Circa Group, and Mr Ross Hampton, CEO of AFPA visiting the pre-commercial facility in Melbourne on Friday.

Mr Eric Hutchinson, Federal MP for Lyons, Mr John Laugher, Vice President Strategy and Business Development at Norske Skog, Mr Tony Duncan, CEO of Circa Group, and Mr Ross Hampton, CEO of AFPA visiting the pre-commercial facility in Melbourne on Friday.

FPA issued a media release welcoming the recent announcement of a joint venture between Circa Group and Norske-Skog to build a large scale prototype manufacturing bio-solvents at the Boyer paper mill site in Tasmania. Mr Ross Hampton said, “This new project would deliver significant economic benefits and is an excellent example of a breakthrough development in the emerging global market for the use of sustainable bio-chemicals using the IP developed by Circa Group. However, there remain regulatory and trade access barriers for the commercialisation of the product in key markets such as Europe and the United States, in terms of the internationalassessment and accreditation of new products such as Cyrene in the market place.” The federal member for Lyons, Eric Hutchinson, said “The State Government support for the build phase of the project is to be applauded. This project will provide much needed jobs and investment in the Tasmanian economy. Addressing the regulatory access issue in international markets is the next key priority. I am working to assist in any way I can, particularly through the commercialisation process to deliver what I think could be a new biochemical technology industry in Tasmania.”